Cargando…

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients

OBJECTIVES: To compare the anti-inflammatory effect of sitagliptin and glimepiride by measuring CRP in overweight Type-2 diabetic patients. METHODS: This clinical trial was conducted at diabetic clinic of Islam Central Hospital, Sialkot over a period of six months from June to November 2017. A total...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussain, Mazhar, Rafique, Muhammad Aamir, Iqbal, Javed, Akhtar, Lubna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500845/ https://www.ncbi.nlm.nih.gov/pubmed/31086519 http://dx.doi.org/10.12669/pjms.35.2.645

Ejemplares similares

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
por: Saad, Mohamed I., et al.
Publicado: (2015)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Serum concentrations of C-reactive protein (CRP) in lean and overweight dogs
por: Hillström, Anna, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Neutrophil lymphocyte ratio (NLR): A well assessment tool of glycemic control in type 2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2017)

Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study
por: Devarajan, T. V., et al.
Publicado: (2017)

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
por: Kim, Yonghyun, et al.
Publicado: (2018)

Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Surveillance of Patulin in Apple, Grapes, Juices and Value-Added Products for Sale in Pakistan
por: Hussain, Shabbir, et al.
Publicado: (2020)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

C-Reactive Protein (CRP) and Leptin Receptor in Obesity: Binding of Monomeric CRP to Leptin Receptor
por: Sudhakar, Manu, et al.
Publicado: (2018)

Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
por: Mubashir, Muaz, et al.
Publicado: (2022)

Role of C Reactive Protein (CRP) in Leptin Resistance
por: Hribal, Marta Letizia, et al.
Publicado: (2014)

On detection of periodicity in C-reactive protein (CRP) levels
por: Dorraki, Mohsen, et al.
Publicado: (2018)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease
por: Ullah, Irfan, et al.
Publicado: (2021)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels
por: Wetterö, Jonas, et al.
Publicado: (2021)

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
por: Nomoto, Hiroshi, et al.
Publicado: (2016)

A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation
por: Ahmed, Mazhar, et al.
Publicado: (2023)

C-Reactive Protein (CRP) and Autoimmune Disease: Facts and Conjectures
por: Szalai, Alexander J.
Publicado: (2004)

Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?
por: Kraus, Virginia B., et al.
Publicado: (2007)

No Reduction of Atherosclerosis in C-reactive Protein (CRP)-deficient Mice
por: Teupser, Daniel, et al.
Publicado: (2011)

Validity of C-reactive protein (CRP) for diagnosis of neonatal sepsis
por: Hisamuddin, Effat, et al.
Publicado: (2015)

Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease
por: Hussain, Mazhar, et al.
Publicado: (2016)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Ionic strength-sensitive and pH-insensitive interactions between C-reactive protein (CRP) and an anti-CRP antibody
por: Oka, Yuka, et al.
Publicado: (2022)

The influence of sugar–protein complexes on the thermostability of C-reactive protein (CRP)
por: Mateescu, Andreea Lorena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9kgvojanen565aj3qm41gv6pnr